Logo 1 Logo 2

Clinical Trial Details

Trial ID: L1737
Source ID: NCT00081484
Associated Drug: Epoetin Alfa Or Beta
Title: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Anemia
Interventions: DRUG: epoetin alfa or beta|DRUG: methoxy polyethylene glycol-epoetin beta [Mircera]
Outcome Measures: Primary: Change in hemoglobin concentration, Weeks 1-36 | Secondary: Number of patients maintaining average Hb concentration within +/- 1g/dL of average baseline Hb concentration, Weeks 29-36|RBC transfusions, Weeks 1-36|AEs, laboratory parameters, vital signs, Throughout study
Sponsor/Collaborators: Sponsor: Hoffmann-La Roche
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 336
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2004-06
Completion Date: 2006-03
Results First Posted:
Last Update Posted: 2016-11-02
Locations: Covina, California, 91723, United States|Los Alamitos, California, 90720, United States|Los Angeles, California, 90073, United States|San Diego, California, 92123, United States|San Diego, California, 92161, United States|Tampa, Florida, 33617, United States|Honolulu, Hawaii, 96813, United States|South Holland, Illinois, 60473, United States|Baton Rouge, Louisiana, 70884, United States|Shreveport, Louisiana, 71101, United States|Shreveport, Louisiana, 71103, United States|Boston, Massachusetts, 02135, United States|Kalamazoo, Michigan, 49007, United States|Columbus, Mississippi, 39705, United States|Tupelo, Mississippi, 38801, United States|St. Louis, Missouri, 63128, United States|Hackensack, New Jersey, 07601, United States|Flushing, New York, 11355, United States|New York, New York, 10025, United States|Orchard Park, New York, 14127, United States|Cleveland, Ohio, 44109, United States|Cleveland, Ohio, 44195, United States|Oregon City, Oregon, 97045, United States|Erie, Pennsylvania, 16502, United States|Lewistown, Pennsylvania, 17044, United States|Philadelphia, Pennsylvania, 19106, United States|Philadelphia, Pennsylvania, 19140, United States|Philadelphia, Pennsylvania, 19141, United States|Columbia, South Carolina, 29209, United States|Charlottesville, Virginia, 22908, United States|Norfolk, Virginia, 23507-1901, United States|Ottawa, Ontario, K1H 7W9, Canada|Toronto, Ontario, M5G 2C4, Canada|Greenfield Park, Quebec, J4V 2H1, Canada|Montreal, Quebec, H3G 1A4, Canada|Aix En Provence, 13616, France|Chambery, 73011, France|Hyeres, 83400, France|Le Kremlin-bicetre, 94275, France|Nantes, 44093, France|Paris, 75970, France|Rouen, 76031, France|Erlangen, 91054, Germany|München, 80804, Germany|Nürnberg, 90431, Germany|Como, 22100, Italy|Modena, 41100, Italy|Pavia, 27100, Italy|Rzeszow, 35-055, Poland|Warszawa, 02-006, Poland|Carnaxide, 2799-523, Portugal|Porto, 4099-001, Portugal|Setubal, 2910-446, Portugal|Ponce, 00732, Puerto Rico|San Juan, 00936-5067, Puerto Rico|Alicante, 03010, Spain|Madrid, 28007, Spain|Kaohsiung, 833, Taiwan|Taichung, 407, Taiwan|Taipei, 100, Taiwan|Bangkok, Thailand|Glasgow, G4 OSF, United Kingdom|Hertford, SG1 4AB, United Kingdom|London, E1 1BB, United Kingdom|Salford, M6 8HD, United Kingdom|Swansea, SA6 6NL, United Kingdom
URL: https://clinicaltrials.gov/show/NCT00081484

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress